 |
|
|
| |
CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION
|
| |
| |
CROI 2020 March 8-11
Reported by Jules Levin
CROI: http://www.croiwebcasts.org/p/2020croi/croi/466
CROI: LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS - (03/11/20)
CROI: ATLAS-2M Study: Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study - Every-2-Month Maintenance CAB + RPV Noninferior to Monthly Dosing for 48 Weeks - (03/09/20)
CROI: ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing - press release - (03/09/20)
Susan Ford1, Herta Crauwels2, Kelong Han3, Stefaan Rossenu2, Feifan Zhang3, Jenny O. Huang4, David A. Margolis5, Kenneth Sutton5, Krischan J. Hudson5, Peter
1GlaxoSmithKline, Research Triangle Park, NC, USA,2Janssen, Beerse, Belgium,3GlaxoSmithKline, Collegeville, PA, USA,4GlaxoSmithKline, Mississauga, Canada,5ViiV Healthcare, Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
